Open AccessThe Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives
Author(s) -
Weber Christopher J.,
Carrillo Maria C.,
Jagust William,
Jack Clifford R.,
Shaw Leslie M.,
Trojanowski John Q.,
Saykin Andrew J.,
Beckett Laurel A.,
Sur Cyrille,
Rao Naren P.,
Mendez Patricio Chrem,
Black Sandra E.,
Li Kuncheng,
Iwatsubo Takeshi,
Chang ChiungChih,
Sosa Ana Luisa,
Rowe Christopher C.,
Perrin Richard J.,
Morris John C.,
Healan Amanda M.B.,
Hall Stephen E.,
Weiner Michael W.
Publication year - 2021
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1002/trc2.12226
Subject(s) - neuroimaging , alzheimer's disease neuroimaging initiative , data science , disease , psychology , medicine , neuroscience , alzheimer's disease , computer science
The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW‐ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public‐private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI‐1, ADNI‐GO, ADNI‐2, and ADNI‐3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW‐ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW‐ADNI researchers who shared updates from ADNI‐3 and their vision for ADNI‐4.